Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes.

Jason A Collett, Victor Ortiz-Soriano, Xilong Li, Alexander H Flannery, Robert D Toto, Orson W Moe, David P Basile, Javier A Neyra
{"title":"Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes.","authors":"Jason A Collett, Victor Ortiz-Soriano, Xilong Li, Alexander H Flannery, Robert D Toto, Orson W Moe, David P Basile, Javier A Neyra","doi":"10.1186/s13054-022-03976-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Interleukin-17 (IL-17) antagonism in rats reduces the severity and progression of AKI. IL-17-producing circulating T helper-17 (TH17) cells is increased in critically ill patients with AKI indicating that this pathway is also activated in humans. We aim to compare serum IL-17A levels in critically ill patients with versus without AKI and to examine their relationship with mortality and major adverse kidney events (MAKE).</p><p><strong>Methods: </strong>Multicenter, prospective study of ICU patients with AKI stage 2 or 3 and without AKI. Samples were collected at 24-48 h after AKI diagnosis or ICU admission (in those without AKI) [timepoint 1, T1] and 5-7 days later [timepoint 2, T2]. MAKE was defined as the composite of death, dependence on kidney replacement therapy or a reduction in eGFR of ≥ 30% from baseline up to 90 days following hospital discharge.</p><p><strong>Results: </strong>A total of 299 patients were evaluated. Patients in the highest IL-17A tertile (versus lower tertiles) at T1 had higher acuity of illness and comorbidity scores. Patients with AKI had higher levels of IL-17A than those without AKI: T1 1918.6 fg/ml (692.0-5860.9) versus 623.1 fg/ml (331.7-1503.4), p < 0.001; T2 2167.7 fg/ml (839.9-4618.9) versus 1193.5 fg/ml (523.8-2198.7), p = 0.006. Every onefold higher serum IL-17A at T1 was independently associated with increased risk of hospital mortality (aOR 1.35, 95% CI: 1.06-1.73) and MAKE (aOR 1.26, 95% CI: 1.02-1.55). The highest tertile of IL-17A (vs. the lowest tertile) was also independently associated with higher risk of MAKE (aOR 3.03, 95% CI: 1.34-6.87). There was no effect modification of these associations by AKI status. IL-17A levels remained significantly elevated at T2 in patients that died or developed MAKE.</p><p><strong>Conclusions: </strong>Serum IL-17A levels measured by the time of AKI diagnosis or ICU admission were differentially elevated in critically ill patients with AKI when compared to those without AKI and were independently associated with hospital mortality and MAKE.</p>","PeriodicalId":92888,"journal":{"name":"Critical care (Houten, Netherlands)","volume":" ","pages":"107"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008961/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care (Houten, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13054-022-03976-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Interleukin-17 (IL-17) antagonism in rats reduces the severity and progression of AKI. IL-17-producing circulating T helper-17 (TH17) cells is increased in critically ill patients with AKI indicating that this pathway is also activated in humans. We aim to compare serum IL-17A levels in critically ill patients with versus without AKI and to examine their relationship with mortality and major adverse kidney events (MAKE).

Methods: Multicenter, prospective study of ICU patients with AKI stage 2 or 3 and without AKI. Samples were collected at 24-48 h after AKI diagnosis or ICU admission (in those without AKI) [timepoint 1, T1] and 5-7 days later [timepoint 2, T2]. MAKE was defined as the composite of death, dependence on kidney replacement therapy or a reduction in eGFR of ≥ 30% from baseline up to 90 days following hospital discharge.

Results: A total of 299 patients were evaluated. Patients in the highest IL-17A tertile (versus lower tertiles) at T1 had higher acuity of illness and comorbidity scores. Patients with AKI had higher levels of IL-17A than those without AKI: T1 1918.6 fg/ml (692.0-5860.9) versus 623.1 fg/ml (331.7-1503.4), p < 0.001; T2 2167.7 fg/ml (839.9-4618.9) versus 1193.5 fg/ml (523.8-2198.7), p = 0.006. Every onefold higher serum IL-17A at T1 was independently associated with increased risk of hospital mortality (aOR 1.35, 95% CI: 1.06-1.73) and MAKE (aOR 1.26, 95% CI: 1.02-1.55). The highest tertile of IL-17A (vs. the lowest tertile) was also independently associated with higher risk of MAKE (aOR 3.03, 95% CI: 1.34-6.87). There was no effect modification of these associations by AKI status. IL-17A levels remained significantly elevated at T2 in patients that died or developed MAKE.

Conclusions: Serum IL-17A levels measured by the time of AKI diagnosis or ICU admission were differentially elevated in critically ill patients with AKI when compared to those without AKI and were independently associated with hospital mortality and MAKE.

Abstract Image

Abstract Image

AKI危重患者的血清IL-17水平较高,并与较差的预后相关
背景:大鼠白细胞介素-17 (IL-17)拮抗剂可降低AKI的严重程度和进展。产生il -17的循环T辅助-17 (TH17)细胞在AKI危重患者中增加,表明该途径在人类中也被激活。我们的目的是比较急性肾损伤与非急性肾损伤危重患者血清IL-17A水平,并研究其与死亡率和主要肾脏不良事件(MAKE)的关系。方法:对ICU 2期或3期无AKI患者进行多中心前瞻性研究。在AKI诊断后24-48 h或ICU入院(无AKI者)[时间点1,T1]和5-7天后[时间点2,T2]采集样本。MAKE被定义为死亡、依赖肾脏替代治疗或eGFR在出院后90天内较基线下降≥30%。结果:共评估299例患者。T1时IL-17A水平最高的患者(相对于IL-17A水平较低的患者)有更高的疾病敏锐度和共病评分。AKI患者IL-17A水平高于无AKI患者:T1 1918.6 fg/ml (692.0-5860.9) vs 623.1 fg/ml (331.7-1503.4), p结论:AKI诊断或ICU入院时的血清IL-17A水平在AKI危重患者中与非AKI患者相比有差异升高,并且与住院死亡率和MAKE独立相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信